Editorial Commentary
SURPASS-PEDS: clinical promise and priorities for future research on tirzepatide treatment for youth with type 2 diabetes
AME Clinical Trials Review
2026;
4:
43
.
(25 August 2026)
Editorial Commentary
Concurrent immune checkpoint blockade with chemoradiation: when more is less
AME Clinical Trials Review
2026;
4:
42
.
(25 August 2026)
Editorial Commentary
Lessons from PACIFIC-2 and the evolving landscape of unresectable stage III non-small cell lung cancer—when synergy blunts the benefit
AME Clinical Trials Review
2026;
4:
41
.
(25 August 2026)
Editorial Commentary
Phacogoniotomy for advanced primary angle-closure glaucoma, from conceptual appeal to randomized evidence
AME Clinical Trials Review
2026;
4:
40
.
(25 August 2026)
Editorial Commentary
Sunvozertinib redraws the map in EGFR ex20ins mutant non-small cell lung cancer
AME Clinical Trials Review
2026;
4:
39
.
(25 August 2026)
Editorial Commentary
Ribociclib in early breast cancer: interpreting the 4-year outcomes of the NATALEE trial
AME Clinical Trials Review
2026;
4:
38
.
(25 August 2026)
Editorial Commentary
Balloon-based percutaneous coronary intervention in multilayer in-stent restenosis
AME Clinical Trials Review
2026;
4:
37
.
(25 August 2026)
Editorial Commentary
Interpreting JCOG1409 (MONET): what does non-inferiority really mean for minimally invasive oesophagectomy?
AME Clinical Trials Review
2026;
4:
36
.
(25 August 2026)
Editorial Commentary
HARMONi-6 trial: a further development in the management of advanced squamous non-small-cell lung cancer
AME Clinical Trials Review
2026;
4:
35
.
(25 August 2026)
Editorial Commentary
Direction of guidelines about drug-coated balloon angioplasty for in-stent restenosis of drug-eluting stents
AME Clinical Trials Review
2026;
4:
34
.
(25 August 2026)
Editorial Commentary
Timing, technique and the challenges in non-culprit vessel revascularisation: a critical look at the iMODERN Trial
AME Clinical Trials Review
2026;
4:
33
.
(25 August 2026)
Review Article
Rituximab combinations in hairy cell leukemia
AME Clinical Trials Review
2026;
4:
32
.
(25 August 2026)
Editorial Commentary
The dry retina paradox: interpreting MERLIN in clinical practice
AME Clinical Trials Review
2026;
4:
31
.
(25 June 2026)
Editorial Commentary
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
AME Clinical Trials Review
2026;
4:
30
.
(25 June 2026)
Editorial Commentary
Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon
AME Clinical Trials Review
2026;
4:
29
.
(25 June 2026)
Editorial Commentary
We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer
AME Clinical Trials Review
2026;
4:
28
.
(25 June 2026)
Editorial Commentary
Precision in practice: a new standard in early-relapsing HR+ breast cancer
AME Clinical Trials Review
2026;
4:
27
.
(25 June 2026)
Editorial Commentary
Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)
AME Clinical Trials Review
2026;
4:
26
.
(25 June 2026)
Editorial Commentary
EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer
AME Clinical Trials Review
2026;
4:
25
.
(25 June 2026)
Editorial Commentary
Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?
AME Clinical Trials Review
2026;
4:
24
.
(25 June 2026)
Editorial Commentary
Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study
AME Clinical Trials Review
2026;
4:
23
.
(25 June 2026)
Editorial Commentary
Extensive-stage small cell lung cancer: progress, slowly but surely
AME Clinical Trials Review
2026;
4:
22
.
(25 June 2026)
Letter to the Editor
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review
2026;
4:
21
.
(25 April 2026)
Letter to the Editor
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
AME Clinical Trials Review
2026;
4:
20
.
(25 April 2026)
Editorial Commentary
Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward
AME Clinical Trials Review
2026;
4:
19
.
(25 April 2026)
Editorial Commentary
Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?
AME Clinical Trials Review
2026;
4:
18
.
(25 April 2026)
Editorial Commentary
Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study
AME Clinical Trials Review
2026;
4:
17
.
(25 April 2026)
Editorial Commentary
Cachexia, cytokines, and caution: lessons from tocilizumab in advanced pancreatic ductal adenocarcinoma
AME Clinical Trials Review
2026;
4:
16
.
(25 April 2026)
Editorial Commentary
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review
2026;
4:
15
.
(25 April 2026)
Editorial Commentary
Not so fast—should neoadjuvant chemotherapy be routine in resectable pancreatic cancers?
AME Clinical Trials Review
2026;
4:
14
.
(25 April 2026)